Vivos Inc. RDGL
Set alert
0.04 USD 0.00 -1.97%
At close · Oct 30
0.0419 Day range 0.045
0.0391 52-week range 0.1244
- YTD
- -34.98%
- 1 year
- -43.61%
- Open
- 0.044
- Prev close
- 0.0457
- Mkt cap
- 22.14M
- Vol
- 197.16K
- Avg vol
- 938.89K
- EPS
- -0.01
- P/E
- 0.00
More statistics
- Low
- 0.0419
- High
- 0.045
1M chart
Signals (8)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Mar 18, 2024 | Dec 1, 2023 | 0.00 | -0.01 | — | — |
| Nov 6, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 4, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
News
- Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard
- Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
- Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
- Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
- Vivos Therapeutics Announces Material Debt Reduction
- Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology
- Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
- Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
- Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
- Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
Your note
Sign in to keep a note on RDGL — it syncs with the Stock Master app.